Pharmacodynamics (PD) evaluation is a cornerstone of preclinical drug discovery, characterizing the relationship between drug concentration, target engagement, and the resulting biological effect. It answers the critical question: "What does the drug do to the body?" Reliable PD data is essential for validating mechanism of action, establishing Proof of Concept (PoC), and defining the therapeutic window. BOC Sciences offers comprehensive in vivo PD evaluation services utilizing a wide array of validated animal models and functional assay systems. We help clients assess potency, evaluate efficacy, and optimize dosing regimens for small molecules, biologics, and novel therapeutics, providing the robust data needed to confidently select lead candidates for further development.
BOC Sciences delivers customized Pharmacodynamic evaluations with rapid turnaround times, helping you make data-driven decisions in the drug discovery pipeline.
We offer a broad portfolio of syngeneic, xenograft (CDX), and humanized models. Key readouts include tumor volume measurement, survival analysis, and flow cytometry profiling of tumor-infiltrating immune cells to assess anti-cancer efficacy.
Our platform includes models for arthritis, dermatitis, IBD, and other inflammatory conditions. We quantify efficacy through phenotypic scoring, histological examination, and cytokine profiling (ELISA/MSD) to measure immune modulation.
We evaluate therapeutics for diabetes, obesity, and NASH using diet-induced obesity (DIO) and genetic models. Endpoints include glucose tolerance tests (OGTT/IPGTT), insulin sensitivity, lipid profiling, and liver histology.
For CNS drug candidates, we provide behavioral batteries assessing cognition, motor function, anxiety, and pain. These functional readouts are correlated with tissue analysis to link physiological changes with pharmacological intervention.
We identify and quantify proximal and distal biomarkers to verify target engagement. Techniques include Western Blotting, qPCR, and immunohistochemistry (IHC) to track phosphorylation events or gene expression changes post-dosing.
We integrate pharmacokinetic (PK) data with pharmacodynamic results to model the exposure-response relationship. This holistic approach helps optimize dosing schedules and predict efficacy in subsequent development stages.
BOC Sciences adapts experimental designs to suit the unique properties of various drug classes, ensuring relevant and accurate pharmacodynamic assessment.
Submit your compound details and target indication. We will design a bespoke in vivo efficacy study to demonstrate the therapeutic potential of your asset.
Our scientists review your target and compound properties to recommend the most appropriate animal models and functional endpoints for your specific therapeutic area.
We define experimental groups, dosing routes, schedules, and sampling time points. A detailed study protocol is generated for client review and approval.
The study is conducted in our controlled facilities. We perform dosing, in-life observations, and sample collection (blood, tissue) with rigorous adherence to the protocol.
Samples are analyzed (histology, biomarkers, etc.), and data is statistically evaluated. A final report containing methods, raw data, and efficacy conclusions is delivered.
We assist research teams in validating novel hypotheses under limited funding by offering flexible Pilot Studies and "Quick-Kill" experiments that generate critical preliminary data for grants and publications without the overhead of full-scale studies.
To help startups secure investor confidence and meet tight fundraising deadlines, we provide Fast-Track Efficacy Screening with rapid turnaround times, delivering robust data packages that support critical milestones and quick "Go/No-Go" decisions.
We support pharmaceutical companies facing capacity constraints by delivering scalable, Pivotal PD Studies; our team handles complex, multi-arm protocols with GLP-like standards to ensure data readiness for crucial project milestones.
For virtual companies lacking internal wet-lab infrastructure, we act as a dedicated R&D partner offering End-to-End PD Management, overseeing the entire lifecycle from protocol design to bioanalysis so you can focus on strategy.
Partner with BOC Sciences to access a diverse range of validated animal models and functional assays. Our scientific depth and flexible study designs provide the clear, actionable efficacy data you need to drive your drug development forward.
We maintain a vast library of validated disease models covering oncology, immunology, metabolic disorders, and CNS, allowing for immediate study initiation and relevant disease simulation.
For novel targets, our team can develop and validate custom animal models or functional assays, tailored specifically to the mechanism of action of your therapeutic candidate.
We integrate diverse analytical technologies, including in vivo imaging, flow cytometry, histology, and molecular biology, to provide a holistic view of pharmacodynamic activity.
Our experienced study directors provide consultative support throughout the project, ensuring flexible adaptation to emerging data while maintaining high scientific standards and reproducibility.
Client Needs: A biotech client needed to assess the in vivo efficacy of a novel kinase inhibitor in a lung cancer Cell-Derived Xenograft (CDX) model. The goal was to establish a dose-response relationship and confirm target engagement within the tumor tissue.
Challenges: Previous studies showed high variability in tumor growth rates, making it difficult to distinguish statistically significant drug effects from biological noise. Additionally, the client needed to differentiate between general toxicity (weight loss) and specific anti-tumor activity driven by the Mechanism of Action (MoA).
Solution: BOC Sciences designed a robust study using BALB/c nude mice with stratified randomization to ensure uniform baseline tumor volumes. We implemented a multi-arm dosing schedule (Vehicle, Low, Mid, High). Crucially, we integrated downstream biomarker analysis, with tumors harvested at the study endpoint for Western blot analysis of phosphorylated target proteins to directly correlate phenotypic tumor shrinkage with molecular target inhibition.
Outcome: The compound demonstrated a dose-dependent Tumor Growth Inhibition (TGI) of 75% at the high dose with no significant body weight loss. Biomarker analysis confirmed robust suppression of target phosphorylation, validating the MoA and supporting the client's candidate advancement.
Client Needs: A pharmaceutical developer required a pharmacodynamic evaluation of a therapeutic peptide intended for Rheumatoid Arthritis (RA). They needed to demonstrate both symptomatic relief and structural joint preservation in a relevant animal model.
Challenges: The peptide had a short half-life, requiring an optimized dosing regimen to maintain therapeutic levels. Furthermore, the client struggled to correlate observations (paw swelling) with histological improvements, which was critical for proving disease-modifying potential.
Solution: We utilized the gold-standard Collagen-Induced Arthritis (CIA) rat model. BOC Sciences optimized the dosing frequency based on preliminary PK data. Our solution included a comprehensive readout strategy comprising daily symptomatic scoring of paw edema, ELISA-based quantification of serum cytokines (TNF-α, IL-6), and detailed histopathological assessment of synovial hyperplasia and cartilage erosion, thereby providing a holistic efficacy profile.
Outcome: The peptide treatment significantly reduced disease scores and preserved joint architecture comparable to the standard of care (Dexamethasone). The clear correlation between cytokine reduction and histological protection provided compelling Proof of Concept (PoC) data.
Client Needs: A client sought to evaluate a small molecule agonist for its potential to improve glucose tolerance and insulin sensitivity in a Diet-Induced Obesity (DIO) model, a key step for their metabolic disease program.
Challenges: Establishing a stable, homogenous obesity phenotype required a lengthy induction period. The client also needed to detect subtle metabolic shifts without inducing hypoglycemia, requiring highly sensitive functional assays rather than just body weight monitoring.
Solution: BOC Sciences established a robust DIO mouse model (C57BL/6 fed a high-fat diet for 12 weeks). We moved beyond simple weight tracking by performing dynamic metabolic testing, including Oral Glucose Tolerance Tests (OGTT) and Insulin Tolerance Tests (ITT). We also conducted plasma lipid profiling and liver histology to assess effects on hepatic steatosis.
Outcome: The candidate drug significantly improved glucose clearance and insulin sensitivity compared to the vehicle group. The comprehensive data package highlighted the compound's potential as a safe metabolic modulator, triggering the next phase of lead optimization.
Pharmacodynamics evaluation is essential for understanding the functional relationship between candidate compounds and their targets, serving as a key element in assessing biological activity. By systematically analyzing effect magnitude, dose dependency, and response dynamics, clients can more accurately compare molecular options. BOC Sciences delivers structured and reproducible evaluation services to support high-quality research decision-making.
An appropriate model should closely align with the target mechanism and study objectives. BOC Sciences supports clients in selecting or developing tailored pharmacodynamic models based on molecular pathways, functional endpoints, and application scenarios, ensuring results are biologically relevant and interpretable, thereby increasing the practical value of study conclusions.
Data reliability is achieved through standardized workflows and robust quality control. BOC Sciences applies harmonized experimental designs, repeat validation strategies, and statistical analysis methods to minimize variability and ensure consistency. This approach enables clients to obtain stable and trustworthy pharmacodynamic data across different project stages.
Pharmacodynamic results can be used to compare functional differences among candidates, identify key effect indicators, and support project prioritization. In addition to data delivery, BOC Sciences provides expert interpretation based on target biology, helping clients quickly grasp result implications and develop clear, actionable research strategies.
Complex projects often require coordination across multiple technical modules. BOC Sciences leverages integrated service capabilities to ensure efficient alignment between pharmacodynamics evaluation and related research activities, reducing information gaps, improving overall efficiency, and helping clients maintain consistent progress across parallel projects.
The in vivo efficacy study conducted by BOC Sciences was executed flawlessly. The data was clean, the variance was low, and the report provided deep insights into the dose-response relationship of our compound. It gave us the confidence to proceed to the next milestone.
— Dr. Arthur, Director of Biology, Emerging Biotech
We were unsure which animal model would best represent our target indication. The team at BOC Sciences provided excellent consultation, recommending a model that perfectly recapitulated the disease pathology. Their scientific input added immense value to our project.
— Dr. Lucas, Senior Scientist, Pharmaceutical Company
PD evaluation is often a bottleneck, but BOC Sciences delivered results ahead of schedule. Their regular updates on animal health and study progress allowed us to monitor the efficacy trends in real-time. Highly recommended for fast-paced R&D.
— Dr. James, Project Leader, Drug Discovery Institute
Beyond just tumor measurements, the downstream biomarker analysis provided by BOC Sciences helped us confirm our Mechanism of Action. The integration of efficacy data with molecular readouts was seamless and professionally presented.
— Dr. Thomas, VP of Research, Oncology Startup
If you have any questions or encounter issues on this page, please don't hesitate to reach out. Our support team is ready to assist you.
